• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Ariad Pharmaceuticals

Ariad Pharmaceuticals

  1. All
  2. 3rd Party
  1. ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

    ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

  2. Takeda Reports Q3 FY2016 Results and Improves Year-End Outlook

    Takeda Reports Q3 FY2016 Results and Improves Year-End Outlook

  3. Breakthrough Therapies: Market Dynamics and Investment Opportunities - Should Reach $99.2 Billion by 2022 - Research and Markets

    Breakthrough Therapies: Market Dynamics and Investment Opportunities - Should Reach $99.2 Billion by 2022 - Research and Markets

  4. The Top-Performing Funds in 2011's Toughest Category

    These two small-value funds have followed different paths to success in a difficult year for the peer group.

©2017 Morningstar Advisor. All right reserved.